Financial & Business update Q2 (October ’22 – December ‘22)
GeoJunxion NV (ticker: GOJXN.AS) Financial & Business update Q2 (October ’22 – December ‘22) and first half of
Globe Newswire23-02-2023, 14:57
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26